CD20-targeting in B-cell Malignancies: Novel Prospects for Antibodies and Combination Therapies

Overview

Journal Invest New Drugs

Publisher Springer

Specialty Oncology

Date 2016 Apr 15

PMID 27075017

Citations 5

Authors

Yaghoub Safdari

Vahideh Ahmadzadeh

Safar Farajnia

Affiliations

Soon will be listed here.

Abstract

Expression of CD20 antigen by the most of transformed B cells is believed to be the driving force for targeting this molecule by using anti-CD20 monoclonal antibodies. While it is true that most lymphoma/leukemia patients can be cured, these regimens are limited by the emergence of treatment resistance. Based on these observations, development of anti-CD20 monoclonal antibodies and combination therapies have been recently proposed, in particular with the aim to optimize the cytotoxic activity. Here we outline a range of new experimental agents concerning the CD20 positive B-cell tumors which provide high benefit from conventional therapy.

Citing Articles

Primary breast CD20-positive extranodal NK/T cell lymphoma with stomach involvement: a case report and literature review.

Zhang Y, Wang K, Tan Q, Yang K, Wu D, Xu Y Diagn Pathol. 2021; 16(1):103.

PMID: 34749754 PMC: 8573996. DOI: 10.1186/s13000-021-01166-4.

Nanomedicines in B cell-targeting therapies.

Wang J, Yang J, Kopecek J Acta Biomater. 2021; 137:1-19.

PMID: 34687954 PMC: 8678319. DOI: 10.1016/j.actbio.2021.10.024.

Kang D, Cho J, Kim I, Kim M, Kim W, Kim S Cancer Res Treat. 2017; 50(4):1051-1063.

PMID: 29121713 PMC: 6192930. DOI: 10.4143/crt.2017.207.

Prognostic stratification improvement by integrating ID1/ID3/IGJ gene expression signature and immunophenotypic profile in adult patients with B-ALL.

Cruz-Rodriguez N, Combita A, Enciso L, Raney L, Pinzon P, Lozano O J Exp Clin Cancer Res. 2017; 36(1):37.

PMID: 28245840 PMC: 5331651. DOI: 10.1186/s13046-017-0506-4.

Therapeutic antibody targeting of indoleamine-2,3-dioxygenase (IDO2) inhibits autoimmune arthritis.

Merlo L, Grabler S, DuHadaway J, Pigott E, Manley K, Prendergast G Clin Immunol. 2017; 179:8-16.

PMID: 28223071 PMC: 5466478. DOI: 10.1016/j.clim.2017.01.016.

References

Chen R, Frankel P, Popplewell L, Siddiqi T, Ruel N, Rotter A . A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma. Haematologica. 2015; 100(3):357-62. PMC: 4349274. DOI: 10.3324/haematol.2014.117473. View

OBrien S, Lamanna N, Kipps T, Flinn I, Zelenetz A, Burger J . A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. Blood. 2015; 126(25):2686-94. PMC: 4732760. DOI: 10.1182/blood-2015-03-630947. View

Teeling J, Mackus W, Wiegman L, van den Brakel J, Beers S, French R . The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol. 2006; 177(1):362-71. DOI: 10.4049/jimmunol.177.1.362. View

Loken M, Shah V, Dattilio K, Civin C . Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte development. Blood. 1987; 70(5):1316-24. View

Tuscano J, Ma Y, Martin S, Kato J, ODonnell R . The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies alone. Cancer Immunol Immunother. 2011; 60(6):771-80. PMC: 3098984. DOI: 10.1007/s00262-011-0978-6. View

Yan C, Li S, Li Z, Peng H, Yuan X, Jiang L . Human umbilical cord mesenchymal stem cells as vehicles of CD20-specific TRAIL fusion protein delivery: a double-target therapy against non-Hodgkin's lymphoma. Mol Pharm. 2012; 10(1):142-51. DOI: 10.1021/mp300261e. View

Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri G, Bernasconi S . Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood. 2000; 95(12):3900-8. View

Rossi E, Rossi D, Stein R, Goldenberg D, Chang C . A bispecific antibody-IFNalpha2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells. Cancer Res. 2010; 70(19):7600-9. DOI: 10.1158/0008-5472.CAN-10-2126. View

Jensen M, Tan G, Forman S, Wu A, Raubitschek A . CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy. Biol Blood Marrow Transplant. 1998; 4(2):75-83. DOI: 10.1053/bbmt.1998.v4.pm9763110. View

10.

Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D . lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res. 2008; 14(14):4650-7. DOI: 10.1158/1078-0432.CCR-07-4405. View

11.

Zhang L, Kosek J, Wang M, Heise C, Schafer P, Chopra R . Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression. Br J Haematol. 2012; 160(4):487-502. DOI: 10.1111/bjh.12172. View

12.

Hagner P, Man H, Fontanillo C, Wang M, Couto S, Breider M . CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL. Blood. 2015; 126(6):779-89. PMC: 4528065. DOI: 10.1182/blood-2015-02-628669. View

13.

Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P . Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002; 99(3):754-8. DOI: 10.1182/blood.v99.3.754. View

14.

Stanglmaier M, Faltin M, Ruf P, Bodenhausen A, Schroder P, Lindhofer H . Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels. Int J Cancer. 2008; 123(5):1181-9. DOI: 10.1002/ijc.23626. View

15.

Jak M, van Bochove G, Reits E, Kallemeijn W, Tromp J, Umana P . CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101. Blood. 2011; 118(19):5178-88. DOI: 10.1182/blood-2011-01-331702. View

16.

Byrd J, Flynn J, Kipps T, Boxer M, Kolibaba K, Carlile D . Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia. Blood. 2015; 127(1):79-86. PMC: 4705612. DOI: 10.1182/blood-2015-03-634394. View

17.

Reagan M, Seib F, McMillin D, Sage E, Mitsiades C, Janes S . Stem Cell Implants for Cancer Therapy: TRAIL-Expressing Mesenchymal Stem Cells Target Cancer Cells In Situ. J Breast Cancer. 2012; 15(3):273-82. PMC: 3468780. DOI: 10.4048/jbc.2012.15.3.273. View

18.

Boissel L, Betancur-Boissel M, Lu W, Krause D, Van Etten R, Wels W . Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity. Oncoimmunology. 2014; 2(10):e26527. PMC: 3881109. DOI: 10.4161/onci.26527. View

19.

Liu H, Westergard T, Cashen A, Piwnica-Worms D, Kunkle L, Vij R . Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4. Cancer Cell. 2014; 25(4):530-42. PMC: 4097146. DOI: 10.1016/j.ccr.2014.03.008. View

20.

Casulo C, Vose J, Ho W, Kahl B, Brunvand M, Goy A . A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokinetics. Clin Immunol. 2014; 154(1):37-46. PMC: 4348114. DOI: 10.1016/j.clim.2014.06.005. View